Asia
Ascletis Pharma Completes Patient Enrollment in Phase 2 Study of ASC30
Ascletis Pharma (HKG:1672) said it completed patient enrollment in the phase 2 study of its oral drug ASC30 in the U.S., according to a Hong Kong bourse filing Monday.The firm will study the drug as a treatment for type 2 diabetes over a 13-week period. Topline data from the investigation is expected in the third quarter of 2026, according to Ascletis.ASC30 is also being developed as a treatment for obesity.
HKG:1672
